Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Isaac Motamarry

Surgery Gainesville, FL Medical Doctor

NPI 1619110186 CMS profile 209297

1600 Sw Archer Rd, Gainesville, FL 32610

Open in the dashboard

General payments

$114,539

164 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$450,000

7 holdings reported · through program year 2025

Through program year 2025, Isaac Motamarry of Gainesville, FL is reported in the CMS Open Payments database as having received $114,539 across 164 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $450,000 across 7 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,538 16
2024 General $619 9
2023 General $1,597 32
2022 General $102,286 30
2021 General $2,081 37
2020 General $3,571 19
2019 General $2,847 21
2025 Ownership $150,000 2
2024 Ownership $150,000 2
2023 Ownership $150,000 2
2022 Ownership $0 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Isaac Motamarry
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Isaac Motamarry were reported at $1,538. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Isaac Motamarry Surgery median Middle half National median
2019 $2,847 $253 $82–$1,521 $163
2020 $3,571 $131 $40–$706 $114
2021 $2,081 $168 $50–$904 $132
2022 $102,286 $224 $76–$1,218 $149
2023 $1,597 $253 $82–$1,255 $160
2024 $619 $279 $90–$1,381 $164
2025 $1,538 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Centinel Spine, LLC $100,000 1 payment
  2. Intuitive Surgical, Inc. $7,418 29 payments
  3. W. L. Gore & Associates, Inc. $5,085 62 payments
  4. AbbVie, Inc. $281 3 payments
  5. Allergan Inc. $251 4 payments
  6. Davol Inc. $219 4 payments
  7. Kerecis Limited $153 3 payments
  8. Novo Nordisk Inc $142 8 payments
  9. Merck Sharp & Dohme Corporation $136 6 payments
  10. RedHill Biopharma Inc. $105 6 payments
  11. Other $749 38 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Current or prospective ownership or investment interest $100,000 1 payment
  2. Food and Beverage $8,471 152 payments
  3. Education $3,000 1 payment
  4. Travel and Lodging $2,373 9 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $695 1 payment
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $7,418 29 payments
  2. GORE ENFORM Preperitoneal Biomaterial $2,397 32 payments
  3. GORE SEAMGUARD Bioabsorbable Staple Line Reinforce $1,527 10 payments
  4. STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS $517 6 payments
  5. GORE ENFORM Intraperitoneal Biomaterial $471 3 payments
  6. GORE ENFORM Biomaterial $296 4 payments
  7. GORE SYNECOR Biomaterial $284 12 payments
  8. BRIDION $136 6 payments
  9. PHASIX $125 1 payment
  10. SEAMGUARD Bioabsorbable Staple Line Reinforcement $110 1 payment
  11. Other $1,946 69 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

752

Median for General Surgery: 59

Drug cost

$53,844

Median for General Surgery: $393

Branded share of claims

31.5%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 33 $35,508
Eliquis Apixaban Brand 11 $6,434
Creon Lipase/Protease/Amylase Brand 13 $4,022
Naltrexone Hcl Generic 55 $2,259
Omeprazole Generic 145 $1,413
Gabapentin Generic 41 $1,087
Bupropion Hcl Generic 57 $479
Ondansetron Odt Ondansetron Brand 39 $463
Sucralfate Generic 22 $455
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 47 $422

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$113,497

Medicare's payments for the services billed

Medicare patients

200

Average age 71

Services billed

452

134 women, 66 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Diabetes 41%
Chronic kidney disease 39%
Depression 38%
Ischemic heart disease 35%
COPD 29%
Atrial fibrillation 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

164 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record